KDAM-FM (Yankton, SD)
Verified
Radio
KDAM (94.3 FM) is a hot adult contemporary radio station serving Yankton and Vermillion, South Dakota area that is licensed to Hartington, Nebraska. KDAM is owned and operated by Riverfront Broadcasting LLC Source
Actions
Media Outlet details
| Scope | Local |
|---|---|
| Language | English |
| Country | United States of America |
|
Similarweb UVM |
Request pricing |
|
Comscore UVM |
Request pricing |
| Frequency | Daily |
| Days Published | N/A |
Recent Articles
Search ArticlesGuardian Metal Resources PLC Announces Pilot Mountain Technical Report Summary
Guardian Metal Resources plc (‘Guardian Metal’ or the ‘Company’) Publication of Technical Report Summary for Pilot Mountain Guardian Metal Resources plc (NYSE.A:GMTL)(LON:GMET)(OTCQB:GMTLF), a strategic mineral exploration company focused on tungsten in Nevada, USA, is pleased to announce the publication of its Technical Report Summary (“TRS”) for the Pilot Mountain tungsten project (“Pilot Mountain”).
Empire Metals Limited Announces Interim Results
Empire Metals Limited (“Empire” or the “Company”) Interim Results Empire Metals Limited, the AIM-quoted and OTCQX-traded exploration and development company, is pleased to announce its interim results for the six-month period ended 30 June 2026.
InterContinental Hotels Group PLC Announces Transaction in Own Shares – August 27
The Company announces that on 26 August 2026 it purchased the following number of its ordinary shares of 20340/399pence each through Goldman Sachs International (“GSI“) on the London Stock Exchange in accordance with the authority granted by shareholders at the Company’s Annual General Meeting on 8 May 2025 (the “Purchase“). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026.
RoboSense Reports 2026 Interim Results, with Robotics LiDAR Sales Volume Up 510.4% Year over Year
H1 2026 revenue increased 30.2% year over year to RMB 1.02 billion. Total LiDAR sales volume rose 169.6% year over year to 719,200 units. LiDAR sales volume for robotics and other applications increased 510.4% year over year to 282,600 units. RoboSense expanded its product matrix beyond LiDAR into three robotics component categories — “Eyes,” “Skin,” and “Muscles” — with the first commercial deliveries of new products beginning in Q3 2026. , /PRNewswire/ — RoboSense Technology Co., Ltd.
Gaotu Techedu Announces Second Quarter 2026 Unaudited Financial Results
, /PRNewswire/ — Gaotu Techedu Inc. (NYSE: GOTU) (“Gaotu” or the “Company”), a leading technology-driven education company in China focused on enabling lifelong learning through AI-powered solutions, today announced its unaudited financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Highlights[1] Net revenues were RMB1,670.1 million, increased by 20.2% from RMB1,389.4 million in the same period of 2025.
SCP Standard Capital Partners AG: VANEA Defence unveils ATOMZA®, the first production-ready drone defence system for civilian operators
ATOMZA® is the first counter-drone mitigation solution that can be deployed by civilian operators without sovereign enforcement powers. VANEA is opening up counter-UAS capabilities to airports, large-scale events, critical infrastructure and other sites exposed to security threats or espionage – a market previously restricted to public security authorities with the legal mandate to actively counter drones.
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn’s Disease
Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn’s disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV) induction , /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for SKYRIZI® (risankizumab) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely...
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52 Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE , /PRNewswire/ — Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE® (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE).
hVIVO acquires CRS Berlin, expanding expertise into dermatology and women’s health markets
London, UK – 27 August 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces the acquisition of CRS Clinical Research Services Berlin GmbH (“CRS Berlin”).
Digital Realty breaks ground on new state-of-the-art data center in Switzerland
ZURICH, Aug. 27, 2026 (GLOBE NEWSWIRE) — Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, today announced the start of construction on a new, state-of-the-art data center in Glattbrugg. The facility – ZUR4 – will provide 15 megawatts (MW) of IT capacity across approximately 6,300 m2 of space, serving the growing demand for digital infrastructure in one of Europe’s most important data and financial hubs.